AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06352112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive Exercises
Description: HE program in which different placements of the upper and lower extremities were used in standing, sitting and supine positions, and the participants were asked to perform the exercises with a hypopressive maneuver to maintain apnea and rib cage expansion for approximately 10 seconds. Exercises were started with three repetitions a day, and then the number of repetitions was increased to five and/or 10, depending on the participant's tolerance. The exercises were performed as home exercises.
Study NCT05644054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Patients will be administered a one-time dosage of 0.2 mg/kg THC oil (AXIBAN, T10/C2, manufactured by Panaxia Pharmaceuticals, Lod, Israel)
Study NCT05644054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be administered a one-time dosage of 0.2 mg/kg of a placebo consisting of an inactive oil.
Study NCT05060276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-3258
Description: Intravenous infusion of STI-3258 will be given (one infusion every three weeks).
Study NCT06771778 — intervention group
Intervention type: OTHER
Intervention: Survey using a questionnaire.
Description: A Qualtrics link was provided for current and former NICU RDNs to complete a 10-minute online survey that provided an optional gift card for completion. Part 1 of the survey had eight questions, and part 2 had eleven additional questions.
Study NCT06776458 — intervention group
Intervention type: OTHER
Intervention: N/A - Usual Care
Description: Breast cancer survivors will have received usual care aromatase inhibitors for up to 10 years post-diagnosis.
Study NCT05501821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBA1412
Description: Part A, B, C
Study NCT05501821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Part C only
Study NCT05915663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasogastric tube and orogastric tube
Description: nasogastric tube in period 1 and orogastric tube in period 2
Study NCT05915663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orogastric tube and nasogastric tube
Description: orogastric tube in period 1 and nasogastric tube in period 2
Study NCT06776718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vNOTES
Description: vNOTES for benign hysterectomy
Study NCT06776718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginal hysterectomy
Description: vaginal hysterectomy for benign hysterectomy
Study NCT05548933 — intervention group
Intervention type: PROCEDURE
Intervention: non-surgical periodontal therapy
Description: supragingival scaling,subgingival scaling
Study NCT05402189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketodex, Fentanyl
Description: The patients will be randomized into 2 groups : group (KD) and group (OP) . Two 20 ml syringes, labelled loading and another two 20 ml syringes labelled maintenance will be given to each patient according to his group.~Group (KD): patients will receive 1mg/kg ketamine and 1ug/kg dexmiditomidine in their respective loading syringes diluted in 20ml normal saline. Then , they will receive ketamine 0.1 mg/kg /hr and dexmedetomidine0.2ug/kg/hr in their maintenance syringes prepared in 20 ml normal saline in a concentration of 1mg/ml ketamine and 1ug/ml dexmiditomidine respectively .~Group (OP): one of the loading syringes will contain fentanyl in a dose of 2ug/kg diluted in 20 ml normal saline and the other loading syringe will contain normal saline. Then, the patients will receive 0.5ug/kg/hr fentanyl through one of the maintenance syringes while the other syringe contains normal saline.
Study NCT03977064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style change and weight reduction
Description: Nutritional, behavioural, and exercise counselling to reduce body weight by 10%, normalise blood glucose, lipids, blood pressure, and testosterone level.
Study NCT04850417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker, aspirin, clopidogrel
Description: Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy
Study NCT04850417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker, aspirin, clopidogrel
Description: Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy
Study NCT05872269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar
Description: 4 Mg Oral Tablet
Study NCT04723446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate
Description: Corsodyl® Alcohol-free is a clear to slightly opalescent oromucosal solution with an odour of peppermint that contains 0.2% w/v chlorhexidine digluconate which is an antimicrobial preparation for external use. It is effective against a wide range of Gram negative and Gram positive vegetative bacteria, yeasts, dermatophyte fungi and lipophilic viruses. It is active against a wide range of important oral pathogens and is therefore effective in the treatment of many common oral conditions.
Study NCT04723446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Peroxyl® -1.5% Hydrogen peroxide
Description: Peroxyl mouthwash is a clear aqua-blue liquid oromucosal solution which 100ml of solution contains 1.5g of Hydrogen peroxide (as 30% Hydrogen Peroxide solution). It is an oral antiseptic cleanser for external use. The principal action is brought about by contact of hydrogen peroxide with peroxidases and catalases present in tissues and saliva, which causes the rapid release of oxygen. This provides mechanical cleansing which flushes out mouth debris and helps in the treatment of oral irritations. This mouthwash is used as a cleanser in the symptomatic relief of minor mouth and gum irritations.
Study NCT04723446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral-B® Gum & Enamel Care -Cetylpyridinium chloride
Description: The Oral-B® Gum \& Enamel Care mouthwash is an oromucosal solution containing Cetylpyridinium chloride (CPC) and used as an adjunct to oral hygiene.
Study NCT06775821 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound or CT of the abdominal aorta
Description: Patient underwent ultrasound or CT of the abdominal aorta
Study NCT06777212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training Program
Description: The Mindfulness Training Program is a 30-day behavioral intervention designed to help children with body-focused repetitive behaviors (BFRBs) such as nail-biting, skin-picking, and hair-pulling. Delivered through JD Health, the program includes daily audio-guided exercises focused on mindfulness techniques such as deep breathing, body scans, and emotional awareness. Children will be encouraged to practice mindfulness for 10-15 minutes each day, with the goal of improving emotional regulation, reducing impulsive behavior, and enhancing self-awareness. Family support is involved, with parents helping children track their progress and offering reinforcement.
Study NCT06777212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Education Program
Description: The Psychosocial Education Program is a 30-day behavioral intervention designed for children with body-focused repetitive behaviors (BFRBs), including nail-biting, skin-picking, and hair-pulling. Delivered through JD Health, the program provides daily educational content in the form of articles and coping strategies. The intervention focuses on improving emotional regulation, promoting family support, and developing positive behavioral strategies. Parents play an active role by reviewing the content with their children and helping them apply the strategies in daily life. Behavioral and psychological assessments are conducted at baseline, one month, and three months to evaluate the program's impact.
Study NCT06527092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: VR is an interactive, multidimensional, computer-simulated environment accessed through a head-mounted device that blocks the view of the real world. This environment is projected in front of the user's eyes through sophisticated head-mounted displays, including a wide field of view and motion tracking systems
Study NCT06527092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bubbles
Description: A colorful light bubble gun was used for bubble therapy, which is one of the distraction methods.
Study NCT06776614 — intervention group
Intervention type: PROCEDURE
Intervention: Decompressive Craniectomy
Description: The DC will be performed through a standard trauma incision, a retro-auricular C-shape or a Kempe incision and execute a 15x15 cm craniotomy with a C-shape durotomy. Dural closure will be at the discretion of the surgeon and the availability of resources, including duroplasty with aponeurotic galea, a suturable dural patch, a non-suturable dural patch, or simply a superficial dural cover with hemostatic materials like Surgicel® or Gelfoam®. There are multiple techniques for DC. The elected technique will be at the discretion of the treating neurosurgeon, but only front-parietal-temporal DC will be considered. The removed bone flap may be stored in an abdominal pouch in the right or left upper abdominal quadrants or by freezing in a bone or blood bank freezer.
Study NCT06776614 — intervention group
Intervention type: PROCEDURE
Intervention: Expansion Craniotomy
Description: The EC will be performed through a retro-auricular C-shape incision and executing a 15x15 cm craniotomy with a C-shape durotomy. Dural closure will be at the discretion of the surgeon and the availability of resources, including duroplasty with aponeurotic galea, a suturable dural patch, a non-suturable dural patch, or simply a superficial dural cover with hemostatic materials like Surgicel® or Gelfoam®. The expansion craniotomy will be finished with a cranioplasty using a full set of 3-5 Rialto plates for bone graft closure. The selected technique will be at the discretion of the treating neurosurgeon, but only front-parietal-temporal EC will be considered.
Study NCT06776939 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy
Description: All patients are subject to both oxygen therapy groups in this randomized cross-over study. Study measurements are performed during several different disconnection sessions. Disconnection sessions can either be short (\<90 min) or long (12 hours). Both short and long disconnection sessions are performed twice; once with conventional oxygen, and once with high-flow tracheal oxygen as respiratory support.
Study NCT06777381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single visit root canal treatment using ProTaper Universal rotary system
Description: single visit endodontic treatment will be performed using ProTaper Universal rotary system for root canal preparation.
Study NCT06777381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single visit root canal treatment using M-Pro rotary system
Description: single visit endodontic treatment will be performed using MPro rotary systems for root canal preparation.
Study NCT06775795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat milk
Description: Participants will consume one portion of plant-based milk alternative (oat) which will provide approximately 200 µg of iodine
Study NCT06775795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soya milk
Description: Participants will consume one portion of plant-based milk alternative (soya) which will provide approximately 200 µg of iodine
Study NCT06775795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk
Description: Participants will consume one portion of semi-skimmed cow's milk which will provide approximately 200 µg of iodine
Study NCT04723446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No rinsing
Description: No rinsing
Study NCT06261307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: Group intervention focusing on musical activities
Study NCT06261307 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Circus intervention
Description: Group intervention focusing on acrobatics and circus activities
Study NCT05372640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study NCT05372640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO
Study NCT05372640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05372640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05372640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo imaging evaluation
Study NCT05427799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey
Description: A mixed flora honey that will be obtained from local producers. and will be consumed by a daily dose of 0.5 g/kg body weight of honey by each participant and will be divided into two doses.
Study NCT05427799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Other carbohydrate alternatives such as jell-o
Description: A daily dose of 0.5 g/kg body weight of Jell-O will be consumed by each participant and will be divided into two doses. Jell-O was selected as a source of sucrose with negligible phenolic capacity.
Study NCT05274425 — intervention group
Intervention type: OTHER
Intervention: Enerzair 150/50/80 μg
Description: There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT05274425 — intervention group
Intervention type: OTHER
Intervention: Enerzair 150/50/160 μg
Description: There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT05826392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adolescent/Young Adult Self-Administered Web-Based Single-Session Intervention
Description: Web-Based, 30-minute self-administered intervention for adolescents
Study NCT05580302 — intervention group
Intervention type: OTHER
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: An anatomical T1 magnetic resonance image (MRI) with high resolution will be acquired on a separate day before the TMS experiment. The image will be imported into the neuronavigation system (Nexstim, Helsinki, Finland) to guide the localization of the primary motor cortex (M1) for laryngeal muscle representation. Prior to M1 mapping for laryngeal muscle representation, mapping of the representation for hand muscle representation will be performed. Hand region excitability (abductor pollicis brevis, APB) will be evaluated by using surface electrodes attached to the right-hand APB muscle. The cSP threshold is defined as the lowest TMS intensity that elicits a cSP in 5 out of 10 consecutive trials. Single-pulse cortical stimulations will be performed during the vocalization of sustained /i/ sound.
Study NCT06156930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group lavender oil
Description: The group will receive aromatherapy massage with a 5% mixture prepared with sesame oil and lavender oil for 10 minutes on both lower leg areas, three times a week for four weeks.
Study NCT06156930 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group sesame oil
Description: The group will receive a massage with sesame oil on both lower leg areas for 10 minutes on each leg, three times a week for four weeks.
Study NCT06402318 — intervention group
Intervention type: DEVICE
Intervention: A&M Breathalyzer PROTECT Kiosk
Description: The A\&M Breathalyzer PROTECT Kiosk will collect the mass spectrum breath readings from each participant, scan speed, and will autoanalyze noise and scan thresholds and sensitivity data.
Study NCT06531291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: 250 mg, po, qd, q3w
Study NCT06531291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: 200 mg, iv, d1, q3w
Study NCT06531291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard chemotherapy
Description: Decided by PI
Study NCT00571740 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV
Study NCT00571740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00571740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00571740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV
Study NCT00571740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00571740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV
Study NCT00571740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00571740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV
Study NCT00571740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT05446701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum level of FAM19A5
Description: Detection of serum level of FAM19A5 of patients and controls by using ELISA technique.
Study NCT05453227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
Study NCT05453227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
Study NCT04911777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentarlandir™ UPPTA
Description: Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)
Study NCT04911777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
Study NCT04911777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
Study NCT06128330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid bolus 20 mg/kg
Description: Bolus of tranexamic acid in the standard dose group
Study NCT06128330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid bolus 10 mg/kg
Description: Bolus of tranexamic acid in the low dose group
Study NCT06128330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid bolus 1 mg/kg
Description: Bolus of tranexamic acid in the low dose group (to add into the CPB prime)
Study NCT06128330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid continuous infusion of 1 mg/kg/h in the low dose group
Description: Tranexamic acid continuous infusion during the procedure
Study NCT06480448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical herapy
Description: core stability, strengthening exercises, stationary bicycle training and sustained strechinng exercises.
Study NCT06480448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Treadmill training for 20 minutes three time a week.
Study NCT06162403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: The leads are inserted through a needle. If needed, the study team may give participants anesthetic (for example, as a cream/gel on your skin and/or as an injection) to numb the area where the leads will be injected.
Study NCT04372498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)
Description: This study is conducted as open label, with each patient's response determined with an adaptive Bayesian model based on historical and baseline values for the primary endpoints of the trial. 3 monthly dose escalation steps will assess the efficacy of senicapoc in a dose range (10-40 mg/day) which has been used in prior trials for other indications.
Study NCT05821712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash
Description: mouthwash
Study NCT05821712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.057% sodium fluoride Mouthwash
Description: mouthwash
Study NCT04740710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing and Attention Training
Description: A guided audio recording will instruct participants to alter their breathing and pay attention in specific ways.
Study NCT04740710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing and Attention Training
Description: A guided audio recording will instruct participants to alter their breathing and pay attention in specific ways.
Study NCT04931277 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: stepped surgery in the form of primary phacoemulsification and secondary posterior chamber intraocular lens (PCIOL) implantation in patients with uveitis.